These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19815999)

  • 1. Pharmacogenomics: role in medicines approval and clinical use.
    Novelli G; Borgiani P; Ciccacci C; Di Daniele N; Sirugo G; Papaluca Amati M
    Public Health Genomics; 2010; 13(5):284-91. PubMed ID: 19815999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics: bench to bedside.
    Weinshilboum R; Wang L
    Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics in Europe: barriers and opportunities.
    Gurwitz D; Zika E; Hopkins MM; Gaisser S; Ibarreta D
    Public Health Genomics; 2009; 12(3):134-41. PubMed ID: 19204415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response.
    Rukov JL; Shomron N
    Trends Mol Med; 2011 Aug; 17(8):412-23. PubMed ID: 21652264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy at the beginning of the genomic era].
    Stoica O; Braha E; Ungureanu G
    Rev Med Chir Soc Med Nat Iasi; 2002; 107(2):240-6. PubMed ID: 12638267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.
    Piana C; Surh L; Furst-Recktenwald S; Iolascon A; Jacqz-Aigrain EM; Jonker I; Russo R; van Schaik RH; Wessels J; Della Pasqua OE
    J Clin Pharmacol; 2012 May; 52(5):704-16. PubMed ID: 21566202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of pharmacogenomics for anesthesia providers.
    Ama T; Bounmythavong S; Blaze J; Weismann M; Marienau MS; Nicholson WT
    AANA J; 2010 Oct; 78(5):393-9. PubMed ID: 21067087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should pharmacogenomic studies be required for new drug approval?
    Relling MV; Hoffman JM
    Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.
    Stingl Kirchheiner JC; Brockmöller J
    Clin Pharmacol Ther; 2011 Feb; 89(2):198-209. PubMed ID: 21209614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of pharmacogenomics.
    Somogy A
    Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.